2023 World Conference on Lung Cancer (Posters)-EP12.01. Lazertinib in Pretreated Epidermal Growth Factor Receptor T790M-Mutated Advanced Non-small Cell Lung Cancer: A Real-World Multicenter Study

EP12.01. Lazertinib in Pretreated Epidermal Growth Factor Receptor T790M-Mutated Advanced Non-small Cell Lung Cancer: A Real-World Multicenter Study - PDF(Slides)

Back to course

Pdf Summary

A real-world multicenter study was conducted to evaluate the efficacy and safety of Lazertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with pretreated EGFR T790M-mutated advanced non-small cell lung cancer. The primary outcome measure was progression-free survival (PFS), and secondary outcomes included overall survival (OS), time-to-treatment failure (TTF), duration of response (DOR), objective response rate (ORR), and disease control rate (DCR). <br /><br />The study included patients who had previously been treated with an EGFR-TKI and found that Lazertinib showed durable disease control both systematically and intracranially. The efficacy and safety of Lazertinib were recapitulated in a real-world setting, reflecting routine clinical practice in Korea. The drug exhibited a high level of selectivity for sensitizing EGFR mutations and had manageable side effects. <br /><br />The study also analyzed various subgroups, including patients with different EGFR mutations, CNS metastasis status, T790M mutation detection method, and Lazertinib dose reduction status. The results showed a favorable progression-free survival for patients with exon 19 deletion mutations compared to those with L858 mutations. Additionally, Lazertinib demonstrated efficacy in patients with CNS metastasis and regardless of the detection method used for T790M mutation. <br /><br />Overall, Lazertinib demonstrated promising results in the treatment of pretreated EGFR T790M-mutated advanced non-small cell lung cancer. These findings will contribute to the understanding and use of Lazertinib in routine clinical practice, providing valuable real-world data for clinicians.

Asset Subtitle

Beung-chul Ahn

Meta Tag

Speaker Beung-chul Ahn

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

Lazertinib

EGFR tyrosine kinase inhibitor

pretreated EGFR T790M-mutated advanced non-small cell lung cancer

progression-free survival

overall survival

time-to-treatment failure

duration of response

objective response rate

disease control rate

real-world data